Nesina

Chemical Namealogliptin
Dosage FormTablet (oral; 6.25 mg, 12.5 mg, 25 mg)
Drug ClassInhibitors
SystemEndocrine
CompanyTakeda
Approval Year2013

Indication

  • Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Last updated on 6/23/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Nesina (alogliptin) Prescribing Information.2022Takeda Pharmaceuticals America, Inc., Lexington, MA
Document TitleYearSource
Effects of DPP4 inhibitors on renal outcomes in diabetes mellitus: a systematic review and meta-analysis.2021Indian Journal of Endocrinology and Metabolism
Real‑world adherence, persistence, and in‑class switching during use of dipeptidyl peptidase‑4 inhibitors: a systematic review and meta‑analysis involving 594,138 patients with type 2 diabetes. 2020Acta Diabetologica
Ethnic differences in efficacy and safety of alogliptin: a systematic review and meta-analysis.2018Diabetes Therapy
The efficacy and safety of dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a Bayesian network meta-analysis of 58 randomized controlled trials. 2018Acta Diabetologica
Comparative effectiveness of adding alogliptin to metformin plus sulfonylurea with other DPP-4 inhibitors in type 2 Diabetes: a systematic review and network meta-analysis. 2017Diabetes Therapy
Gastrointestinal adverse events of dipeptidyl peptidase 4 inhibitors in type 2 diabetes: a systematic review and network meta-analysis. 2017Clinical Therapeutics
Cardiovascular safety of incretin-based therapies in type 2 diabetes: systematic review of integrated analyses and randomized controlled trials.2017Advances in Therapy
Effect of dipeptidyl peptidase-4 inhibitors on heart failure: a network meta-analysis.2017Value in Health
The effects of dipeptidyl peptidase-4 inhibitors on bone fracture among patients with type 2 diabetes mellitus: a network meta-analysis of randomized controlled trials.2017PLoS One
Dipeptidyl peptidase-4 inhibitors and the risk of heart failure: a systematic review and meta-analysis.2017CMAJ Open